Noetic Fund

Bloom is a versatile platform that specializes in selling original brand outlets from curated lists of international brands. It allows customers to experience the convenience of trying on clothes ordered online in their homes before making a payment, with a straightforward return process for items that do not meet their preferences. Additionally, Bloom offers a range of baby products, including gear, toddler furniture, and eco-friendly options. The platform aims to enhance the shopping experience by combining quality products with user-friendly services, catering to the needs of families and individuals looking for both style and functionality.

Apollo is a wellness product, the first clinically validated wearable that actively helps the body recover from stress. Apollo Neuroscience is a wellness product not intended to treat psychiatric disorders such as generalized anxiety disorder, social anxiety disorder, and panic disorder. Apollo is not a substitute for professional medical care.

CaaMTech is the foremost drug discovery and lead optimization company focused on engineering psychedelic drugs that meet the standards of modern medicine. CaaMTech is improving the health and happiness of humankind by creating and optimizing psychedelic compounds and formulations through rigorous science and continuous innovation.

Sana Health is an audio-visual neuromodulation device, that provides anxiety relief on-demand - multiple applications in pain and mental health, 2 pivotal studies are underway in Fibromyalgia (FDA designated breakthrough device) and Neuropathic Pain. Anxiety and PTSD trials starting in Q2 2022, DoD grant for PTSD. SOSV, Founders Fund, Noetic Fund, Harmonix, Dreamit, Esplanade, Bridge Builders Collective, Menlo Ventures.

Merlyn Mind is a technology company that provides AI-based solutions to various industries. It optimizes wake-word architecture and remote control to wake Merlyn on demand. The company puts the power of artificial intelligence in the hands of teachers, allowing them to control technology in their classrooms more naturally. Its first product, Merlyn, is an AI-powered digital assistant purpose-built for education. Merlyn Mind was launched in 2018 and is based in New York.

Apollo is a wellness product, the first clinically validated wearable that actively helps the body recover from stress. Apollo Neuroscience is a wellness product not intended to treat psychiatric disorders such as generalized anxiety disorder, social anxiety disorder, and panic disorder. Apollo is not a substitute for professional medical care.

Woven Science is a Life Sciences platform dedicated to building the complete solution for mental healthcare. Woven is building the infrastructure to become one of the first vertically integrated patient care systems in mental healthcare from drug development all the way through to distribution (clinics) while striking a balance between purpose and profit through its model of mutuality. It was the first company in the industry to give indigenous people a seat at the table with 10% of realized profits going towards supporting a select group of nonprofits that focus on indigenous culture and ecosystem preservation.

Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy. Mental health worldwide has reached epidemic proportions and novel treatments have not kept pace with the urgent need to treat depression, anxiety, drug addiction and many other devastating diseases. Our purpose is to accelerate treatments and fundamentally improve mental health.

Bexson Biomedical is developing a unique formulation of ketamine for chronic and acute pain disorders.

Beckley Psytech operates as a psychedelic medicine company. The company is involved in exploring the therapeutic potential of psychedelic substances, such as psilocybin and other compounds, for mental health treatment. The company envisions the integration of clinically validated psychedelic medicines into contemporary medical practices to assist individuals coping with depression and other significantly debilitating neuropsychiatric conditions characterized by a substantial unmet need.

Eleusis is a clinical stage life science company dedicated to unlocking the therapeutic potential of serotonin 2A receptor agonists, commonly referred to as psychedelics, through the mitigation and management of psychoactivity

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands, and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on Twitter, LinkedIn, YouTube, and Instagram.

Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression. The company is involved in researching and developing psilocybin therapy, a psychedelic compound found in certain mushrooms, as a potential treatment for depression. Compass Pathways conducts clinical trials and research to assess the safety and efficacy of psilocybin-assisted therapy in patients who have not responded to conventional depression treatments. The company's goal is to bring evidence-based innovation to mental health care and address the significant unmet need for effective and accessible treatments for depression.